Citius Oncology Stock Forecast

CTOR's stock price has decreased by -93.92% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 2 analysts with 12-month price forecasts for Citius Oncology stock have an average target of 4.50, with a low estimate of 3.00 and a high estimate of 6.00. The average target predicts an increase of 566.67% from the current stock price of 0.68.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$3.00	$4.50	$6.00	$6.00
Change	+344.44%	+566.67%	+788.89%	+788.89%

* Price targets were last updated on Nov 27, 2024.

Analyst Ratings

The average analyst rating for Citius Oncology stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25
Strong Buy	2	2	2
Buy	0	0	0
Hold	0	0	0
Sell	0	0	0
Strong Sell	0	0	0
Total	2	2	2

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Michael Okunewitch Maxim Group	Maxim Group	Strong Buy Initiates $3	Strong Buy	Initiates	$3	+344.44%	Nov 27, 2024
Jason Kolbert EF Hutton	EF Hutton	Strong Buy Maintains $6	Strong Buy	Maintains	$6	+788.89%	Aug 13, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

n/a

from 106.16M

Revenue Next Year

n/a

EPS This Year

n/a

from -0.31

EPS Next Year

n/a

Fiscal Year	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Sep 30, 2022	Sep 30, 2023	Sep 30, 2024	Sep 30, 2025	Sep 30, 2026	Sep 30, 2027
Revenue	29.26M	74.34M	106.16M
Revenue Growth	-	154.11%	42.80%	-	-	-
EPS	-0.32	-0.19	-0.31	-	-	-
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-
No. Analysts	-	-	-	3	3	3

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	30.1M	76.5M	109.3M
Avg	29.3M	74.3M	106.2M
Low	28.1M	71.4M	102.0M

Revenue Growth

Revenue Growth	2025	2026	2027
High	-71.6%	161.6%	47.0%
Avg	-72.4%	154.1%	42.8%
Low	-73.5%	144.1%	37.2%

EPS Forecast

EPS
High
Avg
Low

EPS Growth

EPS Growth
High
Avg
Low

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.